Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Meta-analysis of VDR Cdx2 polymorphism and prostate cancer risk

From: Role of vitamin D receptor gene Cdx2 and Apa1 polymorphisms in prostate cancer susceptibility: a meta-analysis

   Homozygote (AA vs. GG) Heterozygote (GA vs. GG) Dominant model (AA + GA vs. GG) Recessive model (AA vs. GA + GG)
Analysis N OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%)
Overall 9 1.11 (0.93–1.33) 0.23 32.3 0.97 (0.88–1.06) 0.53 12.9 0.99 (0.91–1.08) 0.80 28.4 1.12 (0.95–1.31) 0.16 17.6
Ethnicity
Caucasian 6 1.13 (0.92–1.39) 0.23 23.0 0.93 (0.84–1.03) 0.201 0 0.96 (0.88–1.06) 0.45 4.4 1.15 (0.94–1.41) 0.15 16.7
African American 1 1.80 (0.97–3.32) 0.06 1.54 (0.81–2.92) 0.18 1.70 (0.94–3.10) 0.08 1.26 (0.91–1.75) 0.16
Hispanic White 1 0.49 (0.17–1.36) 0.17 0.83 (0.52–1.31) 0.43 0.77 (0.50–1.19) 0.24 0.52 (0.18–1.43) 0.20
Mixed 1 0.94 (0.58–1.50) 0.80 1.15 (0.91–1.44) 0.22 1.12 (0.90–1.39) 0.31 0.89 (0.56–1.42) 0.64
Source of control
PB 8 1.11 (0.92–1.33) 0.259 40.7 0.95 (0.86–1.04) 0.32 0 0.97 (0.89–1.06) 0.54 23.8 1.12 (0.95–1.32) 0.16 27.7
HB 1 1.11 (0.93–1.32) 0.686 1.26 (0.88–1.80) 0.19 1.25 (0.89–1.75) 0.19 1.07 (0.52–2.18) 0.85
HWE in controls
Yes 8 1.15 (0.95–1.40) 0.133 34.3 % 0.97 (0.89–1.07) 0.65 22.1 0.99 (0.91–1.09) 0.99 34.6 1.15 (0.97–1.36) 0.09 20.2
No 1 0.87 (0.54–1.40) 0.58 0.91 (0.69–1.21) 0.53 0.90 (0.69–1.17) 0.46 0.90 (0.57–1.43) 0.67
  1. P P values for Z test, OR odds ratio, CI confidence intervals, HB hospital–based studies, PB population-based studies, HWE Hardy–Weinberg equilibrium